Expert Interview
A Second Look: Discussing prime editing, how it compares to CRISPR/Cas9, and it's potential in future therapeutics.
Ticker(s): PRME, VRTX, CRSPYang Yang, PhD is an associate professor in the Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University College of Pharmacy, also affiliated with Purdue Institute for Integrative Neuroscience. Dr. Yang graduated with dual bachelor’s degrees from Shanghai University. Dr. Yang completed a PhD degree atGeorgia State University. Dr. Yang then moved to Yale University School of Medicine as a postdoctoral fellow, studying pharmacogenetics of chronic pain syndromes. He was promoted to Associate Research Scientist and led a small team to use iPSCsderived sensory neurons to establish "pain-in-a-dish" model. Dr. Yang joined the faculty of Purdue University as an Assistant Professor in 2017 and was promoted to Associate Professor in 2023. Currently, a major direction in the Yang lab is to understand the disease mechanisms of SCN2A-related autism and epilepsy. We also
develop next-generation therapeutic interventions to treat these devastating SCN2Arelated diseases including small molecules, antisense oligonucleotides, as well as viruses, and CRISPR-based gene therapies.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
